文献速递临床免疫分子诊断临床血液与体液

乙肝核心相关抗原在慢性乙肝和肝细胞癌患者中的临床评价

Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients.
PubMed 文献 · Clin Chim Acta · 2018-07-17

该研究评价HBcrAg检测在慢性乙肝和肝细胞癌患者中指示HBV载量的价值,并分析HBcrAg/cccDNA与HCC复发的关联。HBcrAg与HBV DNA正相关,且在HBV DNA≤4 log IU/mL时仍与cccDNA相关;肝内cccDNA和血清HBcrAg高者无复发生存率显著更低。

要点

  • HBcrAg与HBV DNA正相关,不受HBeAg状态影响。
  • HBV DNA≤4 log IU/mL时HBcrAg仍与cccDNA相关。
  • 肝内cccDNA和血清HBcrAg高者HCC复发风险更高。

核心结论

  • HBcrAg可作为评估HBV载量的生物标志物,并可用于监测HCC患者肝内cccDNA。
  • HBcrAg可作为HCC患者的预后预测指标。

研究设计与样本

  • 采用化学发光酶免疫法检测HBcrAg,实时PCR法检测89例HCC患者肝组织cccDNA。

主要发现

  • HBcrAg与HBV DNA正相关,不论HBeAg状态。
  • 血清HBV DNA>4 log IU/mL时,HBcrAg和HBV DNA均与cccDNA相关。
  • 血清HBV DNA≤4 log IU/mL时,HBV DNA与cccDNA无关系,但HBcrAg与cccDNA仍呈 modest 相关。
  • 肝内cccDNA高和血清HBcrAg高的HCC患者无复发生存率显著低于低水平者(p=0.035,p=0.003)。

关键数值与推荐

  • HBcrAg与HBV DNA正相关,不受HBeAg状态影响。
  • HBV DNA>4 log IU/mL时HBcrAg和HBV DNA均与cccDNA相关。
  • HBV DNA≤4 log IU/mL时HBcrAg仍与cccDNA相关。
  • 肝内cccDNA高者无复发生存率更低(p=0.035)。
  • 血清HBcrAg高者无复发生存率更低(p=0.003)。

临床怎么用

  • 可用HBcrAg辅助评估慢性乙肝和HCC患者的HBV载量。
  • 在HBV DNA≤4 log IU/mL时,HBcrAg可帮助监测cccDNA。
  • HBcrAg和肝内cccDNA高水平提示HCC复发风险较高,可用于预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B core-related antigen (HBcrAg) has been revealed as an important marker of Hepatitis B virus (HBV) infection recently. We aimed to evaluate the HBcrAg assay for indication of HBV loads in chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) patients and assess the association between HBcrAg/cccDNA and HCC recurrence. METHODS: HBcrAg was measured by chemiluminescence enzyme immunoassay. Intrahepatic covalently closed circular DNA (cccDNA) was measured by real-time PCR with TaqMan fluorescent probes based on liver specimens from 89 HCC patients. RESULTS: HBcrAg correlated positively with HBV DNA irrespective of HBeAg status. Both HBcrAg and HBV DNA were associated with cccDNA in patients with elevated serum HBV DNA (>4 log IU/mL). In patients with non-elevated HBV DNA (≤4 log IU/mL), no relationship between HBV DNA and cccDNA was observed, but we still documented a modest correlation between HBcrAg and cccDNA. Finally, the recurrence-free survival rates were significantly lower in HCC patients with high intrahepatic cccDNA and serum HBcrAg levels than those with low cccDNA/HBcrAg levels (p = 0.035, p = 0.003 respectively). CONCLUSIONS: HBcrAg not only can serve as a biomarker to assess HBV loads in patients as well as provide a good method for monitoring cccDNA in HCC, but also can be used as a good prognostic predictor for HCC patients.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Chen S, Jia J, Gao Y, et al. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients. Clin Chim Acta. 2018. PMID: 30025756. doi:10.1016/j.cca.2018.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。